

1 **Persistent while declined neutralizing antibody responses in the convalescents of**
2 **COVID-19 across clinical spectrum during the 16 months follow up**

3

4 Yang Yang^{1†}, Minghui Yang^{1†}, Yun Peng^{1†}, Yanhua Liang^{1†}, Jinli Wei¹, Li Xing¹,
5 Liping Guo¹, Xiaohe Li¹, Jie Li¹, Jun Wang¹, Mianhuan Li¹, Zhixiang Xu¹, Mingxia
6 Zhang¹, Fuxiang Wang¹, Yi Shi², Jing Yuan^{1*}, Yingxia Liu^{1*}

7

8 ¹Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research
9 Center for infectious disease, State Key Discipline of Infectious Disease, Shenzhen
10 Third People's Hospital, Second Hospital Affiliated to Southern University of Science
11 and Technology, Shenzhen, China

12 ²CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of
13 Microbiology, Chinese Academy of Sciences, Beijing, China

14

15 †Contributed equally.

16 *Contributed equally.

17

18 Correspondence to: Dr Liu, email: yingxialiu@hotmail.com; Dr Yuan, email:
19 13500054798@139.com;

20

21 **Word count:** 3499.

22 **Abstract**

23 Elucidation the kinetics of neutralizing antibody response in the coronavirus disease
24 2019 (COVID-19) convalescents is crucial for the future control of the COVID-19
25 pandemic and vaccination strategies. Here we tested 411 sequential plasma samples
26 collected up to 480 days post symptoms onset (d.a.o) from 214 convalescents of
27 COVID-19 across clinical spectrum without re-exposure history after recovery and
28 vaccination of SARS-CoV-2, using authentic SARS-CoV-2 microneutralization (MN)
29 assays. COVID-19 convalescents free of re-exposure and vaccination could maintain
30 relatively stable anti-RBD IgG and MN titers during 400~480 d.a.o after the peak at
31 around 120 d.a.o and the subsequent decrease. Undetectable neutralizing activity
32 started to occur in mild and asymptomatic infections during 330 to 480 d.a.o with an
33 overall rate of 14.29% and up to 50% for the asymptomatic infections. Significant
34 decline in MN titers was found in 91.67% COVID-19 convalescents with $\geq 50\%$
35 decrease in MN titers when comparing the available peak and current MN titers (\geq
36 300 d.a.o). Antibody-dependent immunity could also provide protection against most
37 of circulating variants after one year, while significantly decreased neutralizing
38 activities against the Beta, Delta and Lambda variants were found in most of
39 individuals. In summary, our results indicated that neutralizing antibody responses
40 could last at least 480 days in most COVID-19 convalescents despite of the obvious
41 decline of neutralizing activity, while the up to 50% undetectable neutralizing activity
42 in the asymptomatic infections is of great concern.

43

44 **Introduction**

45 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh
46 member of coronaviruses that has been found to infect human beings in late
47 December, 2019, in Wuhan, China^{1,2}. The pandemic of SARS-CoV-2 is ongoing and
48 has caused over 209 million human infections with over 4.4 million fatal cases
49 worldwide until now (<https://covid19.who.int/>). Notably, asymptomatic infections
50 account for up to 40% of all the SARS-CoV-2 infections, and silent transmission
51 during the pre-symptomatic and asymptomatic stages are responsible for more than
52 50% of the overall attack rate in COVID-19 outbreaks³⁻⁶. Therefore,
53 antibody-mediated protective immunity induced either by natural infection or
54 vaccination is of great importance for the control of COVID-19 pandemic.

55 Neutralizing antibodies (NAbs) rapidly rise after infection and maintained for
56 years to decades by long-lived plasma and memory B cells in most acute viral
57 infections, playing vital roles in the viral clearance and protection against viral
58 diseases⁷. Studies have shown that the antibody response induced by coronavirus in
59 human beings tends to wane over time, and varies among types of coronaviruses and
60 the severity of the disease⁸. Seasonal human coronaviruses including HCoV-229E,
61 HCoVOC43, HCoV-NL63, and HCoV-HKU1 induce short-lasting antibody response,
62 and reinfection with the same seasonal coronavirus occurred frequently at 12 months
63 after infection⁹. However, the two coronavirus that cause severe disease in human
64 beings including SARS-CoV and Middle East Respiratory Syndrome coronavirus
65 (MERS-CoV) induce stronger and more durable antibody responses up to 3 years^{8,10-14}.
66 Recent data from animal models, therapeutic use of neutralizing monoclonal
67 antibodies and convalescent plasma suggest the critical role of neutralizing antibody
68 in controlling SARS-CoV-2 infection and reinfection¹⁵⁻²², while a key question yet to

69 be addressed is whether COVID-19 convalescents could maintain long-lasting
70 antibody mediated protective immunity. Studies have set out to investigate the
71 dynamic change and longevity of both binding and neutralizing antibody response in
72 COVID-19 convalescents^{14,23-31}, and the results in a very recent study indicated that
73 neutralizing antibody response in COVID-19 convalescents could maintain up to 300
74 days after symptoms onset (d.a.o) accompanied by waning of neutralizing antibody
75 titers²⁹⁻³¹.

76 Limitations of existing studies included either limited number of cohort, or short
77 duration of follow up, enzyme-linked immunosorbent assay (ELISA) or
78 pseudoparticle neutralization based detection of neutralizing antibody response.
79 Moreover, possible re-exposure to SARS-CoV-2 in the pandemic area of COVID-19
80 could significantly influence the dynamics and longevity of NAb titers in COVID-19
81 convalescents. Owing to the highly efficient control of the COVID-19 endemic in
82 China, cohort in China offers ideal model to evaluate the natural dynamics and
83 longevity of neutralizing antibody responses after SARS-CoV-2 infection. In this
84 study, we investigated the dynamics and longevity of NAb titers up to 480 d.a.o from
85 214 convalescents of COVID-19 across clinical spectrum without any further
86 exposure history after recovery and vaccination of SARS-CoV-2, using authentic
87 virus based microneutralization assay, and tested the neutralizing activity against the
88 circulating variants utilizing SARS-CoV-2 pseudotype neutralization assays.

89

90 **Materials and Methods**

91 **Patient information and sample collection**

92 Subjects presented in this study were laboratory confirmed COVID-19 patients using
93 quantitative real-time PCR (Mabsky Biotech Co.) and admitted to our hospital during
94 January 11 to April 18, 2020 (N=214). These individuals were further divided into
95 severe (including critically ill and severe cases), mild (including mild and moderate
96 patients) and asymptomatic group based on disease severity categorized according to
97 the China National Health Commission Guidelines for Diagnosis and Treatment of
98 SARS-CoV-2 infection. Clinical information and laboratory result were collected at
99 the earliest time-point after hospital admission. Blood samples were collected from
100 the enrolled patients during hospitalization and follow-up. Individuals with any
101 further exposure history after discharge or vaccination of SARS-CoV-2 were ruled out
102 during follow-up. The study protocol was approved by the Ethics Committees of
103 Shenzhen Third People's Hospital (2020-010). Written informed consents were
104 obtained from all patients. The study was conducted in accordance with the
105 International Conference on Harmonisation Guidelines for Good Clinical Practice and
106 the Declaration of Helsinki and institutional ethics guidelines.

107 **Disease severity classification**

108 Disease severity classification was evaluated according to China National Health
109 Commission Guidelines for Diagnosis and Treatment of SARS-CoV-2 infection
110 (seventh version) as previously reported^{32,33}. In brief, laboratory confirmed patients
111 with fever, respiratory manifestations and radiological findings indicative of
112 pneumonia were considered moderate cases. Laboratory confirmed patients who met
113 any of the following were considered to have severe COVID-19: 1) respiratory
114 distress (respiration rate $\geq 30/\text{min}$; 2) resting oxygen saturation $\leq 93\%$, or 3) arterial

115 oxygen partial pressure (PaO_2) / fraction of inspired oxygen (FiO_2) \leq 300 mmHg (1
116 mmHg = 0.133 kPa). Laboratory confirmed patients who had any of the following
117 were considered critically ill: 1) respiratory failure requiring mechanical ventilation, 2)
118 shock, or 3) failure of other organs requiring intensive care unit (ICU). The
119 asymptomatic cases were defined as previously reported³⁴.

120 **Cell lines and viruses**

121 African green monkey kidney Vero cell (ATCC, CCL-81) were obtained from ATCC,
122 and 293 cells stably expressing ACE-2 (293-ACE-2) were obtained from Vazyme
123 (Vazyme). Both cell lines were maintained in Dulbecco's minimal essential medium
124 (DMEM) (GIBCO) supplemented with 10% fetal bovine serum (FBS) (Corning) and
125 penicillin (100U/ml)-streptomycin (100mg/ml) (GIBCO). Clinical isolate of
126 SARS-CoV-2 named BetaCoV/Shenzhen/SZTH-003/2020 (EPI_ISL_406594) was
127 isolated the BALF sample of the COVID-19 patient using Vero cell in biosafety level
128 3 (BSL-3) laboratory³⁵. The 50% tissue culture infectious dose (TCID_{50}) assay was
129 done to measure the titre of the viral stock as previously described^{36,37}. In brief, Vero
130 cells in 96-well plates were grown to 90% confluence and infected with 10-fold serial
131 dilutions of the viral stock for 1 h at 37°C. Then the cells were overlaid with fresh
132 DMEM supplemented with 2% FBS. At 4 days post infection, plates were assessed
133 for the lowest dilution in which 50% of the wells exhibited cytopathology. The 50%
134 tissue culture infectious dose (TCID_{50}) values were calculated according to the
135 Reed-Muench method³⁸.

136 **Viral entry inhibition assay with SARS-CoV-2 pseudotyped virus**

137 SARS-CoV-2 pseudotype neutralization assays were conducted to test the neutralizing
138 activity of plasma from COVID-19 convalescents using pseudotyped HIV virus
139 incorporated different variants of SARS-CoV-2 S proteins (Vazyme) as previously

140 reported with some modification³⁹. Serum samples were heat-inactivated at 56 °C for
141 30 min to remove complement activity, and then diluted in white, flat-bottom 96-well
142 plates (Thermo Fisher) with a dilution of 1 in 10 with a total volume of 50µl. Then
143 200 TCID₅₀ of SARS-CoV-2 pseudotyped particles in 50 µl were added to each well
144 and incubated at 37°C for 1h. A total of 4 × 10⁵ ACE2-293T cells (Vazyme) in 100µl
145 complete media were added per well and incubated for 48h at 37°C and 5% CO₂.
146 Firefly luciferase activity (luminescence) was measured using Bright-Light™
147 Luciferase Assay System (Vazyme) and a VARIOSKAN LUX Multi-Mode plate
148 reader (Thermo) according to the manufacture's protocols. Measurements were
149 performed in triplicate and relative luciferase units (RLU) were then converted into
150 neutralization percentages.

151 **Authentic SARS-CoV-2 microneutralization (MN) assays**

152 Authentic SARS-CoV-2 microneutralization assays were performed as we described
153 previously^{23,24,40}. Briefly, plasma samples were heat-inactivated at 56 °C for 30 min to
154 remove complement activity and then serially diluted in 2-folds with DMEM
155 supplemented with 2% FBS from 1:10 to 1:5120. Diluted plasma samples were then
156 mixed with 100 TCID₅₀ of SARS-CoV-2 and incubated at 37°C for 1 hour. The
157 mixture was added to Vero cells and incubated at 37°C and 5% CO₂ for another 96
158 hours. Then cytopathic effect was evaluated and recorded using microscopy. The MN
159 antibody titer was determined as the highest dilution with 50% inhibition of
160 cytopathic effect.

161 **Enzyme-linked immunosorbent assay (ELISA)**

162 RBD and nucleocapsid (N) specific binding immunoglobulin G (IgG) antibodies were
163 measured according to the manufacture's protocols (Sinobio). All plasma samples
164 were heat inactivated at 56 °C for 30 min before use. The plasma samples diluted at

165 1:100 in 5% BSA was added to the high-binding ELISA plates (Corning) pre-coated
166 with antigen (N protein or RBD) and incubated for 2 h at room temperature. Wells
167 were then washed with PBS-T (PBS with 0.05% Tween-20), and secondary antibody
168 was added and incubated for 1 h at room temperature. After another three washes with
169 PBST, tetramethylbenzidine (TMB) substrate (Sangon Biotech) was added at room
170 temperature in the dark. After 15 minutes, the reaction was stopped with a 2M H₂SO₄
171 solution and then the absorbance was measured at 450 nm. A serum sample is
172 considered positive when the OD is fourfold above background.

173 **Statistical analysis**

174 Mann-Whitney U test was used to compare the antibody levels and MN titers between
175 two groups. The Spearman rank correlation coefficient was used for linear correlation
176 analysis between the antibody levels and MN titers. All statistical tests were
177 calculated using SPSS 20.0 for Windows (IBM). P value less than 0.05 was
178 considered statistically significant. The kinetics of anti-RBD IgG and MN titers
179 during follow-up were calculated by the LOESS (locally estimated scatterplot
180 smoothing) curve fitting polynomial regression using R software.

181

182 **Results**

183 **Baseline characteristics of the cohort**

184 A total of 214 laboratory confirmed COVID-19 patients with 51 individuals in severe
185 group, 134 individuals in mild group and 29 individuals in asymptomatic group were
186 included in this study for the analysis of antibody response. This cohort was 46.73%
187 male with an average age of 48 years (range 2-79) (Table 1), and patients in severe
188 group were significantly older than mild and asymptomatic groups. The body mass
189 index (BMI) in severe group was significantly higher than the asymptomatic group.
190 The median days of interval between onset to qPCR negative for SARS-CoV-2 was
191 21, and longer duration of viral shedding was found in severe and mild groups,
192 compared with asymptomatic group. The median duration of hospitalization was 32,
193 20 and 14 days for the severe, mild and asymptomatic groups, respectively. The
194 complete blood count for each patient either on the date of hospital admission or at
195 the earliest time-point showed that expression levels of D-dimer, CRP, IL-6, PCT and
196 LDH were significantly higher in severe and mild groups, while percentage of
197 lymphocyte (LYM), ALB and CD4 count were significantly lower in severe group.
198 Sequential samples were collected at time-points between 1 and 480 d.a.o (the d.a.o
199 for the asymptomatic patients were calculated based on the days post laboratory
200 confirmation) based on the availability, and no individuals with any further exposure
201 history after discharge or vaccination of SARS-CoV-2 were found before the last
202 follow-up (Table 1). A total of 411 plasma samples were collected, with 219 samples
203 collected over 180 d.a.o and 137 samples over 360 d.a.o.

204 **Persistent neutralizing antibody response in COVID-19 convalescents**

205 Firstly, the IgG response against receptor binding domain (RBD) of S glycoprotein
206 and N proteins were measured by ELISA at 1:100 serum dilution over multiple

207 time-points, and the neutralizing antibody titers were measured using
208 microneutralization assay. The results of samples collected over 180 d.a.o were shown
209 in Figure 1. Samples collected between 180 and 330 d.a.o possessed 100% positive
210 rate for anti-RBD IgG, anti-N IgG antibody and detectable (MN titers ≥ 10)
211 neutralizing activity against live SARS-CoV-2 (Figure 1A and 1B). However,
212 individuals with undetectable anti-RBD, anti-N IgG and neutralizing activity were
213 found in follow up days from 331 to 480 d.a.o, and the positive rates varied from 90.9
214 to 100, 90.9 to 100 and 72 to 87.5, respectively (Figure 1A and 1B). Notably, these
215 individuals were mainly from the mild and asymptomatic groups, and the rate of
216 individuals with undetectable neutralizing activity reached 50% (Figure 1C).
217 Meanwhile, the distribution of MN titers obtained during 180 to 480 d.a.o showed that
218 individuals with MN titers ≥ 160 decreased rapidly while proportion of MN titers
219 ranging from negative to 80 increased rapidly along with time, indicating the decline
220 of neutralizing activity in COVID-19 convalescents. Combining IgG response and
221 MN titer measurements, higher coincidence rate of 93.19% were found between
222 anti-RBD IgG and MN tiers than that for anti-RBD IgG and MN tiers (Figure 1E,
223 Figure S1D), and also the significant correlations between MN titers and levels of
224 anti-RBD IgG, especially the severe and mild groups (Figure 1F and Figure S1).

225 **Comparison of neutralizing antibody response among COVID-19 patients across** 226 **clinical spectrum**

227 To determine whether disease severity impacts neutralizing antibody responses in
228 COVID-19 patients, we firstly compared the differences of antibody development
229 within 28 d.a.o among the severe, mild and asymptomatic groups (Figure S2). The
230 positive rates and expression levels of both anti-RBD and anti-N IgG in severe and
231 mild groups increased as the disease progression. For the asymptomatic patients,

232 positive rates of both anti-RBD and anti-N IgG antibody reached 100% as early as
233 0~7 days after laboratory confirmation. The positive rate of neutralizing antibody
234 response showed similar pattern with anti-RBD and anti-N IgG antibody. Then, we
235 further compared the available peak anti-RBD IgG levels and MN titers among the
236 severe, mild and asymptomatic groups. Only the 48 individuals in whom the available
237 peak anti-RBD IgG levels and MN titers occurs before the last time-point and the last
238 time-point is ≥ 300 d.a.o were included in this analysis, with 14, 23, 11 individuals for
239 the severe, mild and asymptomatic groups, respectively (Figure 2). Peak anti-RBD
240 IgG levels in severe and mild groups were comparable, while significantly higher than
241 the asymptomatic group (Figure 2A). Significant differences were found for the
242 current anti-RBD IgG levels among the three groups, with the highest in severe group
243 and the lowest in asymptomatic group (Figure 2C). Peak MN titers in the severe and
244 mild groups showed no statistical significance, while both significantly higher than
245 the asymptomatic group. In detail, peak MN titers for the severe group were all ≥ 80 ,
246 and 50% belonged to range of 640-5120. For the mild group, peak MN titers varied
247 from 10 to 1280, and 26.06% belonged to range of 640-5120. While for the
248 asymptomatic group, all peak MN titers were ≤ 160 , and 81,82% belonged to range of
249 10-80 (Figure 2C and 2E). As to the current MN titers, the severe group showed the
250 highest, and no statistical significance were found between the mild and the
251 asymptomatic groups (Figure 2D and 2F). The current MN titers of severe group
252 mainly belonged to the range of 40-320, while negative to 40 for the mild and
253 asymptomatic group (Figure 2F). These results indicated that COVID-19 patients with
254 more severe disease may develop and maintain stronger neutralizing antibody
255 response.

256 **Dynamic change of neutralizing antibody response in COVID-19 convalescents**

257 To obtain an overall kinetics of antibody response in COVID-19 convalescents, the
258 anti-RBD IgG and MN titers of the 411 plasma samples from 214 were tested and
259 analyzed as a whole, and also stratified into severe, mild and asymptomatic groups.
260 Generally, both the anti-RBD IgG and MN titers reached the peak at around 120 days
261 post illness onset/laboratory confirmation, and then decreased slowly and maintained
262 relatively stable after 400 days post illness onset/laboratory confirmation (Figure 3A
263 and 3B). When comparing among the three groups, the results showed that it took
264 longer (about 150 days) for the severe group to reach the peak anti-RBD IgG and MN
265 titers than the mild (about 120 days) and asymptomatic (about 80 days) groups
266 (Figure S3). To gain a more precise dynamics of antibody response of the COVID-19
267 convalescents, the detailed dynamic changes of anti-RBD IgG, anti-N IgG and MN
268 titers in patients who had measurements at more than three time points during follow
269 up with follow up days ≥ 300 are shown in Figure 4. The profiles of both binding and
270 neutralizing antibody dynamics varied among different individuals. For example, for
271 Patients #01, #09, #14, #19 and #68, both the anti-RBD IgG and nAbs rose and
272 reached the peak rapidly after infection (within 28 d.a.o), and followed by the
273 decrease while still be detectable up to 471 d.a.o. For patients #66, #71, #72, #73, #74,
274 #77, both the anti-RBD IgG and nAbs were detectable within 28 d.a.o and peaked at
275 about 60-90 d.a.o, then decreased but was still be positive up to 477 d.a.o. In contrast,
276 nAbs in patients #67, #75 from the mild group, patients #186, #193, #195 and #196
277 from the asymptomatic group became undetectable at 368 to 470 d.a.o, although
278 anti-RBD IgG was still detectable in some patients (patients #68, #186, #193, #195).

279 Moreover, comparison of the peak (occurred before the last follow up) and the
280 current (> 300 d.a.o) anti-RBD IgG levels showed that COVID-19 convalescents
281 experienced a significant decrease in the anti-RBD IgG levels, and the median ratio of

282 current/peak was 46.38% (range: 13.07%~91.99%) (Figure 3C and 3E). Similar
283 pattern was found for the MN titers (Figure 3D, 3E and 3F). A significant waning of
284 MN titers was also found in the last follow up for 91.67% COVID-19 convalescents
285 with $\geq 50\%$ decrease in MN titers. Notably, stable MN titers were also found in 8.33%
286 individuals.

287 **Neutralizing activity against the circulating variants of SARS-CoV-2 after one** 288 **year**

289 To test whether individuals recovered from SARS-CoV-2 infection early in the
290 pandemic could provide protection against the circulating variants after at least one
291 year, we tested the neutralizing activity using pseudotyped SARS-CoV-2 variants of
292 Alpha, Beta, Gamma, Delta and Lambda (Figure 5). The information of the tested
293 fourteen plasma samples was shown in Table S1. These samples contain samples from
294 COVID-19 convalescents across clinical spectrum, with follow up days varied from
295 377 to 477 and the MN titers varied from 10 to 320. Plasma from the patients with
296 MN titers of 160-320 (patients #47, #58, #172 and #195) could efficiently inhibit the
297 viral entry of pseudotyped SARS-CoV-2 variants at the dilution of 1 in 10 with
298 inhibition rates over 50%, while significantly lower inhibition rates were found in
299 patient #172 and #195 against Beta, Delta and Lambda variants, when compared with
300 the wild type SARS-CoV-2. Samples from patients with MN titers of 40-80 (patients
301 #5, #20, #73, #77 and #197), 3 out of 5 could neutralize the variants of SARS-CoV-2
302 with inhibition rates over 50%, while very low inhibition rates against Beta, Delta and
303 Lambda variants were found in patients #5 (MN titer 80) and #173 (MN titer 40).
304 Meanwhile, significantly lower inhibition rates against Beta, Delta and Lambda
305 variants were also found in all the five individuals. For the individuals with MN titers
306 of 10-20, few individuals (only patient #13) could provide efficient protection against

307 SARS-CoV-2 variants, while most (4/5) showed very low inhibition rates against the
308 most variants (Alpha, Beta, Delta and Lambda), especially Beta, Delta and Lambda
309 variants.

310

311 **Discussion**

312 Detectable levels of neutralizing antibodies against SARS-CoV-2 have been shown to
313 maintain positive at least 300 d.a.o for most individuals²⁹, and most studies supported
314 that neutralizing antibody response started to decline shortly after infection, especially
315 the mild and asymptomatic cases^{14,23,25-29}. Herein, the follow up days was prolonged
316 to 480 d.a.o, and the neutralizing activity was assessed using authentic virus based
317 MN assay. Our results showed that neutralizing activity could be detected for all the
318 63 samples collected during 181~330 d.a.o with MN titers varied from 10 to 640
319 (Figure 1). Individuals with undetectable neutralizing activity were found between
320 331 and 480 d.a.o with an overall rate of 14.29% (Figure 1C). Of concern, none of
321 them were from the severe group, and the rate for the asymptomatic group reached
322 50% (Figure 1C). Distribution of MN titers obtained during 180 to 480 d.a.o showed
323 an obvious trend of decrease along with time. Analysis of antibody dynamics showed
324 that both the anti-RBD IgG and MN titers reached the peak at around 120 days post
325 illness onset/laboratory confirmation, and then decreased slowly and maintained
326 relatively stable after 400 days post illness onset/laboratory confirmation (Figure 3A
327 and 3B) in our cohort. Moreover, when comparing the peak and current MN titers,
328 91.67% of the COVID-19 convalescents showed a decline over 50% in the MN titers
329 (Figure 3F). However, it is worth noting that 8.33% individuals remained stable in
330 MN tiers, both individuals with high (MN titer: 320) or low (MN titer: 20) MN titers
331 (Figure 3F). These data indicated that despite of significant decline in neutralizing
332 antibody response, it could also be maintained at least 480 days in most of the
333 COVID-19 convalescents, while the up to 50% undetectable neutralizing activity in
334 the asymptomatic infections is of great concern. Of note, the decline in neutralizing
335 activity was consistent with the decline in anti-RBD IgG antibody (Figure 3E). Given

336 the high coincidence rate (93.19%) and correlation between levels of anti-RBD IgG
337 and the MN titers (Figure 1E and 1F), presence of the anti-RBD IgG antibody might
338 also indicate the presence of neutralizing activity in COVID-19 convalescents for
339 most cases.

340 SARS-CoV-2 reinfection and vaccine breakthrough have now been frequently
341 reported at months after initial infection or vaccination⁴¹⁻⁴⁷, suggesting that antibody
342 mediated immunity may not confer sterilizing immunity, especially in seropositive
343 individuals with lower amounts of baseline SARS-CoV-2 antibody⁴⁴. Key question to
344 address is what level of the neutralizing antibody response could provide protection
345 against infection or reinfection. Several large cohort studies have shown that
346 antibody-mediated immunity could provide strong protection from reinfection in
347 seropositive individuals up to seven months after infection with protection efficacy
348 varied from 80.5% to 95%⁴⁸⁻⁵⁰. A recent study suggested that the estimated
349 neutralization level for 50% protection against detectable SARS-CoV-2 infection was
350 20.2% of the mean convalescent level, and the estimated neutralization level required
351 for 50% protection from severe infection was about 3% of the mean convalescent
352 level⁵¹. In such case, neutralizing antibody response was sufficient to provide enough
353 protection against reinfection even and severe infection at 480 d.a.o (Figure 1A) for
354 most individuals according to our study. However, SARS-CoV-2 mainly caused
355 asymptomatic to mild infections, and asymptomatic infection constituted up to 40% of
356 all infections⁶. Due to the high rate of undetectable neutralizing antibody response
357 (14.41% for the mild group and 50% for the asymptomatic group) post 330 d.a.o,
358 timely detection and vaccination might be necessary to maintain antibody mediated
359 protection against SARS-CoV-2 for these individuals.

360 S protein particularly the RBD serves as the main target of neutralizing

361 antibodies generated by SARS-CoV-2 infection and vaccination^{52,53}. Studies have
362 found that mutations in S proteins occurred frequently during the natural global
363 transmission or under immune selection pressure and some key mutations have been
364 found to influence the binding between S protein and its receptor or mediate the
365 immune escape against monoclonal antibodies or convalescent plasma⁵⁴⁻⁵⁹. Global
366 concerns have been raised for the potential of immune escape of antibody-dependent
367 immunity, and fortunately recent studies have shown that the currently licensed and
368 widely used inactivated whole virus or mRNA vaccine targeting RBD are still
369 effective against the circulating variants, although partial resistance was observed⁶⁰⁻⁶⁵.
370 In our study, all the patients were admitted to our hospital during January 11 to April
371 18, 2020, most likely infected by the wild type SARS-CoV-2 without the prevalent
372 key mutations. Our results showed that antibody-dependent immunity in individuals
373 with either high (MN titers of 160-320) or low (MN titers of 20-40) MN titers could
374 also provide efficient protection (over 50% inhibition rates at the dilution of 1:10)
375 against most of circulating variants during the 480 days follow up. However,
376 significantly decreased neutralizing activities against the Beta, Delta and Lambda
377 variants were found in most of individuals (Figure 5), which is of great concern.

378 Although reinfection occurred in COVID-19 convalescents or vaccinees,
379 symptomatic reinfections and severe diseases occurred at a lower rate than primary
380 infections^{45,46,48,66}. Accordingly, it is of concern that whether COVID-19
381 convalescents need to receive vaccination and when, and also whether the former
382 vaccinees need for re-vaccination and when. Currently, all the licensed vaccines have
383 been designed to elicit immune responses to the spike protein for providing protection,
384 therefore, it is reasonable for the assumption that the patterns of neutralizing antibody
385 responses post-vaccination will follow the patterns seen in post-infection

386 follow-up^{67,68}. Some recent studies suggested both the binding and neutralizing
387 antibody responses possessed similar rate of decline between vaccination of mRNA
388 vaccine or infection during the first 7 months after vaccination^{69,70}, and our study
389 provide further hints for the durability assessment of vaccine induced antibody
390 response. Furthermore, individuals previously diagnosed with COVID-19 could
391 develop potent humoral immunity rapidly after a single dose of mRNA vaccine⁷¹⁻⁷³. In
392 our study, all the individuals of the cohort did not receive vaccination of SARS-CoV-2
393 before the last follow-up, while about 40 individual started to receive vaccination of
394 inactivated SARS-CoV-2 vaccine, and the specific antibody response of these
395 individuals merits further investigation. Moreover, giving the important role of
396 SARS-CoV-2 specific T cell response in the control of infection, further studies based
397 on this cohort at extended time-points of follow up are required to determine not only
398 the longevity of the neutralizing antibody response but also the SARS-CoV-2 specific
399 T cell response.

400 To our knowledge, this study is the longest follow up for the antibody dynamics
401 of SARS-CoV-2 infection thus far, and our results provide more comprehensive
402 insights into the natural longevity and kinetics of neutralizing antibody response in
403 COVID-19 convalescents across clinical spectrum up to 16 months, and provide
404 important implications for future vaccination strategies.

405

406 **Acknowledgments**

407 This work was supported by grants from National Natural Science Foundation of
408 China (32170936), National Science and Technology Major Project
409 (2021YFC0863300), the Shenzhen Science and Technology Research and
410 Development Project (202002073000001). The authors wish to thank the biological
411 sample bank of the Shenzhen Third People's Hospital for bio-samples and services
412 provided.

413

414 **Declaration of interests**

415 The authors declare that the research was conducted in the absence of any commercial
416 or financial relationships that could be construed as a potential conflict of interest.

417

418 **Contributor**

419 YL, JY and YY were responsible for the concept and design of the study; YY, MY,
420 LG and YP contributed to the analysis and interpretation of data; YL, JW, LX, XL, JL,
421 JW, ML, ZX, MZ and FW enrolled the patients and collected the clinical data; YY and
422 MY drafted the article. YS were responsible for the critical revision for important
423 intellectual content. All authors agree to be accountable for the content of the work.

424

425 Reference

- 426 1 Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*
427 **382**, 727-733, doi:10.1056/NEJMoa2001017 (2020).
- 428 2 Tan, W. *et al.*
- 429 3 Subramanian, R., He, Q. & Pascual, M. Quantifying asymptomatic infection and transmission
430 of COVID-19 in New York City using observed cases, serology, and testing capacity. *Proc Natl*
431 *Acad Sci U S A* **118**, doi:10.1073/pnas.2019716118 (2021).
- 432 4 Mizumoto, K., Kagaya, K., Zarebski, A. & Chowell, G. Estimating the asymptomatic proportion
433 of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship,
434 Yokohama, Japan, 2020. *Euro Surveill* **25**, doi:10.2807/1560-7917.ES.2020.25.10.2000180
435 (2020).
- 436 5 Nishiura, H. *et al.* Estimation of the asymptomatic ratio of novel coronavirus infections
437 (COVID-19). *Int J Infect Dis* **94**, 154-155, doi:10.1016/j.ijid.2020.03.020 (2020).
- 438 6 Oran, D. P. & Topol, E. J. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative
439 Review. *Ann Intern Med* **173**, 362-367, doi:10.7326/m20-3012 (2020).
- 440 7 Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral
441 and vaccine antigens. *N Engl J Med* **357**, 1903-1915, doi:10.1056/NEJMoa066092 (2007).
- 442 8 Sariol, A. & Perlman, S. Lessons for COVID-19 Immunity from Other Coronavirus Infections.
443 *Immunity* **53**, 248-263, doi:10.1016/j.immuni.2020.07.005 (2020).
- 444 9 Edridge, A. W. D. *et al.* Seasonal coronavirus protective immunity is short-lasting. *Nat Med* **26**,
445 1691-1693, doi:10.1038/s41591-020-1083-1 (2020).
- 446 10 Liu, L. *et al.* Longitudinal profiles of immunoglobulin G antibodies against severe acute
447 respiratory syndrome coronavirus components and neutralizing activities in recovered
448 patients. *Scand J Infect Dis* **43**, 515-521, doi:10.3109/00365548.2011.560184 (2011).
- 449 11 Cao, Z. *et al.* Potent and persistent antibody responses against the receptor-binding domain
450 of SARS-CoV spike protein in recovered patients. *Virology* **7**, 299, doi:10.1186/1743-422X-7-299
451 (2010).
- 452 12 Choe, P. G. *et al.* MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea,
453 2015. *Emerg Infect Dis* **23**, 1079-1084, doi:10.3201/eid2307.170310 (2017).
- 454 13 Zhao, J. *et al.* Recovery from the Middle East respiratory syndrome is associated with
455 antibody and T-cell responses. *Sci Immunol* **2**, doi:10.1126/sciimmunol.aan5393 (2017).
- 456 14 Seow, J. *et al.* Longitudinal observation and decline of neutralizing antibody responses in the
457 three months following SARS-CoV-2 infection in humans. *Nat Microbiol* **5**, 1598-1607,
458 doi:10.1038/s41564-020-00813-8 (2020).
- 459 15 Kim, Y. I. *et al.* Critical role of neutralizing antibody for SARS-CoV-2 reinfection and
460 transmission. *Emerg Microbes Infect* **10**, 152-160, doi:10.1080/22221751.2021.1872352
461 (2021).
- 462 16 Bao, L. *et al.* Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. *bioRxiv*,
463 2020.2003.2013.990226, doi:10.1101/2020.03.13.990226 (2020).
- 464 17 Deng, W. *et al.* Primary exposure to SARS-CoV-2 protects against reinfection in rhesus
465 macaques. *Science* **369**, 818-823, doi:10.1126/science.abc5343 (2020).
- 466 18 Weinreich, D. M. *et al.* REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with
467 Covid-19. *N Engl J Med* **384**, 238-251, doi:10.1056/NEJMoa2035002 (2021).
- 468 19 Chen, P. *et al.* SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. *N*

- 469 *Engl J Med* **384**, 229-237, doi:10.1056/NEJMoa2029849 (2021).
- 470 20 Duan, K. *et al.* Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
471 *Proc Natl Acad Sci U S A* **117**, 9490-9496, doi:10.1073/pnas.2004168117 (2020).
- 472 21 Shen, C. *et al.* Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
473 *JAMA* **323**, 1582-1589, doi:10.1001/jama.2020.4783 (2020).
- 474 22 Libster, R. *et al.* Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N*
475 *Engl J Med* **384**, 610-618, doi:10.1056/NEJMoa2033700 (2021).
- 476 23 Wajnberg, A. *et al.* Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
477 *Science* **370**, 1227-1230, doi:10.1126/science.abd7728 (2020).
- 478 24 Wu, F. *et al.* Evaluating the Association of Clinical Characteristics With Neutralizing Antibody
479 Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. *JAMA Intern*
480 *Med* **180**, 1356-1362, doi:10.1001/jamainternmed.2020.4616 (2020).
- 481 25 Zhang, X. *et al.* Viral and Antibody Kinetics of COVID-19 Patients with Different Disease
482 Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study. *Virol Sin* **35**,
483 820-829, doi:10.1007/s12250-020-00329-9 (2020).
- 484 26 Bal, A. *et al.* Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by
485 virus neutralization and commercial assays. *Clin Microbiol Infect*,
486 doi:10.1016/j.cmi.2021.01.003 (2021).
- 487 27 Weisberg, S. P. *et al.* Distinct antibody responses to SARS-CoV-2 in children and adults across
488 the COVID-19 clinical spectrum. *Nat Immunol* **22**, 25-31, doi:10.1038/s41590-020-00826-9
489 (2021).
- 490 28 Crawford, K. H. D. *et al.* Dynamics of Neutralizing Antibody Titers in the Months After Severe
491 Acute Respiratory Syndrome Coronavirus 2 Infection. *J Infect Dis* **223**, 197-205,
492 doi:10.1093/infdis/jiaa618 (2021).
- 493 29 Lau, E. H. Y. *et al.* Neutralizing antibody titres in SARS-CoV-2 infections. *Nat Commun* **12**, 63,
494 doi:10.1038/s41467-020-20247-4 (2021).
- 495 30 Vanshylla, K. *et al.* Kinetics and correlates of the neutralizing antibody response to
496 SARS-CoV-2 infection in humans. *Cell Host Microbe* **29**, 917-929.e914,
497 doi:10.1016/j.chom.2021.04.015 (2021).
- 498 31 Wang, H. *et al.* Dynamics of the SARS-CoV-2 antibody response up to 10 months after
499 infection. *Cell Mol Immunol* **18**, 1832-1834, doi:10.1038/s41423-021-00708-6 (2021).
- 500 32 Yang, Y. *et al.* Plasma IP-10 and MCP-3 levels are highly associated with disease severity and
501 predict the progression of COVID-19. *J Allergy Clin Immunol* **146**, 119-127 e114,
502 doi:10.1016/j.jaci.2020.04.027 (2020).
- 503 33 Liu, Y. X. *et al.* Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral
504 load and lung injury. *National Science Review* **7**, 1003-1011, doi:10.1093/nsr/nwaa037
505 (2020).
- 506 34 Long, Q. X. *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2
507 infections. *Nat Med* **26**, 1200-1204, doi:10.1038/s41591-020-0965-6 (2020).
- 508 35 Liu, C. *et al.* The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by
509 Cryo-EM and Cryo-ET. *Structure* **28**, 1218-1224 e1214, doi:10.1016/j.str.2020.10.001 (2020).
- 510 36 Yang, Y. *et al.* Development of a quadruple qRT-PCR assay for simultaneous identification of
511 highly and low pathogenic H7N9 avian influenza viruses and characterization against
512 oseltamivir resistance. *BMC Infect Dis* **18**, 406, doi:10.1186/s12879-018-3302-7 (2018).

- 513 37 Yang, Y. *et al.* Development of a reverse transcription quantitative polymerase chain
514 reaction-based assay for broad coverage detection of African and Asian Zika virus lineages.
515 *Virology* **32**, 199-206, doi:10.1007/s12250-017-3958-y (2017).
- 516 38 Reed, L. & Muench, H. A simple method for estimating fifty percent endpoints. *Am. J. Hyg* **37**
517 (1938).
- 518 39 Reynolds, C. J. *et al.* Discordant neutralizing antibody and T cell responses in asymptomatic
519 and mild SARS-CoV-2 infection. *Sci Immunol* **5**, doi:10.1126/sciimmunol.abf3698 (2020).
- 520 40 To, K. K. *et al.* Temporal profiles of viral load in posterior oropharyngeal saliva samples and
521 serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
522 *Lancet Infect Dis* **20**, 565-574, doi:10.1016/S1473-3099(20)30196-1 (2020).
- 523 41 Gupta, V. *et al.* Asymptomatic reinfection in two healthcare workers from India with
524 genetically distinct SARS-CoV-2. *Clin Infect Dis*, doi:10.1093/cid/ciaa1451 (2020).
- 525 42 To, K. K. *et al.* COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain
526 confirmed by whole genome sequencing. *Clin Infect Dis*, doi:10.1093/cid/ciaa1275 (2020).
- 527 43 Van Elslande, J. *et al.* Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct
528 strain. *Clin Infect Dis*, doi:10.1093/cid/ciaa1330 (2020).
- 529 44 Letizia, A. G. *et al.* SARS-CoV-2 seropositivity and subsequent infection risk in healthy young
530 adults: a prospective cohort study. *Lancet Respir Med* **9**, 712-720,
531 doi:10.1016/s2213-2600(21)00158-2 (2021).
- 532 45 Butt, A. A. *et al.* Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After
533 Vaccination: Breakthrough SARS-CoV-2 infection. *Int J Infect Dis*,
534 doi:10.1016/j.ijid.2021.08.008 (2021).
- 535 46 Hacisuleyman, E. *et al.* Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J*
536 *Med* **384**, 2212-2218, doi:10.1056/NEJMoa2105000 (2021).
- 537 47 Kustin, T. *et al.* Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern
538 in BNT162b2-mRNA-vaccinated individuals. *Nat Med* **27**, 1379-1384,
539 doi:10.1038/s41591-021-01413-7 (2021).
- 540 48 Hall, V. J. *et al.* SARS-CoV-2 infection rates of antibody-positive compared with
541 antibody-negative health-care workers in England: a large, multicentre, prospective cohort
542 study (SIREN). *Lancet* **397**, 1459-1469, doi:10.1016/s0140-6736(21)00675-9 (2021).
- 543 49 Abu-Raddad, L. J. *et al.* SARS-CoV-2 antibody-positivity protects against reinfection for at least
544 seven months with 95% efficacy. *EClinicalMedicine* **35**, 100861,
545 doi:10.1016/j.eclinm.2021.100861 (2021).
- 546 50 Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K. & Ethelberg, S. Assessment of
547 protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in
548 Denmark in 2020: a population-level observational study. *Lancet* **397**, 1204-1212,
549 doi:10.1016/s0140-6736(21)00575-4 (2021).
- 550 51 Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection
551 from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211,
552 doi:10.1038/s41591-021-01377-8 (2021).
- 553 52 Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell* **184**, 861-880,
554 doi:10.1016/j.cell.2021.01.007 (2021).
- 555 53 Greaney, A. J. *et al.* Complete Mapping of Mutations to the SARS-CoV-2 Spike
556 Receptor-Binding Domain that Escape Antibody Recognition. *Cell Host Microbe* **29**, 44-57.e49,


- 557 doi:10.1016/j.chom.2020.11.007 (2021).
- 558 54 Korber, B. *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
559 Infectivity of the COVID-19 Virus. *Cell* **182**, 812-827 e819, doi:10.1016/j.cell.2020.06.043
560 (2020).
- 561 55 Baum, A. *et al.* Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational
562 escape seen with individual antibodies. *Science* **369**, 1014-1018,
563 doi:10.1126/science.abd0831 (2020).
- 564 56 Greaney, A. J. *et al.* Comprehensive mapping of mutations in the SARS-CoV-2
565 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. *Cell*
566 *Host Microbe*, doi:10.1016/j.chom.2021.02.003 (2021).
- 567 57 Thomson, E. C. *et al.* Circulating SARS-CoV-2 spike N439K variants maintain fitness while
568 evading antibody-mediated immunity. *Cell* (2021).
- 569 58 Wibmer, C. K. *et al.* SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19
570 donor plasma. *bioRxiv*, doi:10.1101/2021.01.18.427166 (2021).
- 571 59 Tegally, H. *et al.* Emergence and rapid spread of a new severe acute respiratory
572 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South
573 Africa. *medRxiv*, 2020.2012.2021.20248640, doi:10.1101/2020.12.21.20248640 (2020).
- 574 60 Supasa, P. *et al.* Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and
575 vaccine sera. *Cell* **184**, 2201-2211.e2207, doi:10.1016/j.cell.2021.02.033 (2021).
- 576 61 Zhou, D. *et al.* Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and
577 vaccine-induced sera. *Cell*, doi:10.1016/j.cell.2021.02.037 (2021).
- 578 62 Wang, P. *et al.* Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature*,
579 doi:10.1038/s41586-021-03398-2 (2021).
- 580 63 Huang, B. *et al.* Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both
581 inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. *bioRxiv*,
582 2021.2002.2001.429069, doi:10.1101/2021.02.01.429069 (2021).
- 583 64 Planas, D. *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
584 *Nature* **596**, 276-280, doi:10.1038/s41586-021-03777-9 (2021).
- 585 65 Lopez Bernal, J. *et al.* Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
586 *N Engl J Med* **385**, 585-594, doi:10.1056/NEJMoa2108891 (2021).
- 587 66 Leidi, A. *et al.* Risk of reinfection after seroconversion to SARS-CoV-2: A population-based
588 propensity-score matched cohort study. *Clin Infect Dis*, doi:10.1093/cid/ciab495 (2021).
- 589 67 Subbarao, K. The success of SARS-CoV-2 vaccines and challenges ahead. *Cell Host Microbe* **29**,
590 1111-1123, doi:10.1016/j.chom.2021.06.016 (2021).
- 591 68 Kim, D. S., Rowland-Jones, S. & Gea-Mallorquí, E. Will SARS-CoV-2 Infection Elicit Long-Lasting
592 Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). *Front Immunol*
593 **11**, 571481, doi:10.3389/fimmu.2020.571481 (2020).
- 594 69 Pegu, A. *et al.* Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2
595 variants. *Science*, doi:10.1126/science.abj4176 (2021).
- 596 70 Widge, A. T. *et al.* Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *N Engl J*
597 *Med* **384**, 80-82, doi:10.1056/NEJMc2032195 (2021).
- 598 71 Krammer, F. *et al.* Antibody Responses in Seropositive Persons after a Single Dose of
599 SARS-CoV-2 mRNA Vaccine. *N Engl J Med* **384**, 1372-1374, doi:10.1056/NEJMc2101667
600 (2021).

601 72 Demonbreun, A. R. *et al.* Comparison of IgG and neutralizing antibody responses after one or
602 two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.
603 *EClinicalMedicine* **38**, 101018, doi:10.1016/j.eclinm.2021.101018 (2021).
604 73 Manisty, C. *et al.* Antibody response to first BNT162b2 dose in previously
605 SARS-CoV-2-infected individuals. *Lancet* **397**, 1057-1058,
606 doi:10.1016/s0140-6736(21)00501-8 (2021).
607


608 **Figures and Tables**

609 **Figure 1. Persistent neutralizing antibody responses in COVID-19 convalescents.**


610 (A) Positive rates of the anti-RBD IgG, anti-N IgG and microneutralization (MN)
611 titers for the 219 plasma samples from 175 COVID-19 convalescents with over 180
612 days follow up. (B) Detailed OD values of anti-RBD IgG, anti-N IgG and LogMN
613 titers of the 219 plasma samples. Specimens with MN titers less than 10 were
614 assigned a value of 5. (C) Dynamic changes of the distribution of the MN titers along
615 with time. (D) Negative rates of anti-RBD IgG and neutralizing activity post 330 d.a.o.
616 (E) Pie chart comparing fraction of samples with anti-RBD IgG and neutralizing
617 activity. (F) Spearman correlation plot between the OD values of anti-RBD IgG and
618 log MN titers. Specimens with MN titers less than 10 were assigned a value of 5.



620 **Figure 2. Comparison of neutralizing antibody response among different clinical**
 621 **spectrum of COVID-19 convalescents.** (A) and (B) The available peak levels of
 622 anti-RBD IgG and MN titers for the severe, mild and asymptomatic groups. (C) and
 623 (D) The current levels of anti-RBD IgG and MN titers for the severe, mild and
 624 asymptomatic groups. Specimens with MN titers less than 10 were assigned a value of
 625 5. (E) and (F) Distribution of the available peak and current MN titers severe, mild
 626 and asymptomatic groups.




628 **Figure 3. Dynamic change of neutralizing antibody response in COVID-19**
629 **convalescents.** (A) and (B) Kinetics of anti-RBD IgG and MN titers against
630 SARS-CoV-2 during the 480 days follow-up. The black solid line represents the fitted
631 curve obtained using the LOESS (locally estimated scatterplot smoothing) curve
632 fitting polynomial regression. Gray band areas represent 95% confidence intervals. (C)
633 and (D) Donor-matched peak and current anti-RBD IgG/MN titers. Only individuals
634 in whom the peak MN titers occur before the last time-point and the last time-point
635 is > 300 d.a.o are included in this analysis (n=42), and each line represents one
636 individual. Specimens with MN titers less than 10 were assigned a value of 5.
637 Individuals in severe, mild and asymptomatic groups are marked in red, blue and
638 purple, respectively. (E) The ratio of current/peak anti-RBD IgG and MN titers for the
639 three groups. (F) Proportion of the different decrease rates in MN titers for the three
640 groups.



641


642

643 **Figure 4. Representative dynamic changes of antibody responses (anti-RBD IgG,**
 644 **anti-N IgG and MN titers) in 31 COVID-19 patients during acute infection and**
 645 **the convalescent phase. Only patients who had measurements at more than three**
 646 **time points during follow up with follow up days ≥ 300 are shown. Specimens with**
 647 **MN titers less than 10 were assigned a value of 5.**




649 **Figure 5. Protection of neutralizing antibody from convalescents of COVID-19**
650 **across clinical spectrum against the circulating variants of SARS-CoV-2.**

651 Neutralizing activity of 14 plasma sample collected at the last time-point (377 to 477
652 d.a.o) from individuals in severe, mild and asymptomatic groups were assessed using
653 pseudotyped SARS-CoV-2 neutralization assay. The inhibition rates of single plasma
654 against pseudotyped SARS-CoV-2 variants of Alpha, Beta, Gamma, Delta and
655 Lambda at the dilution of 1 in 10. The belonged groups and MN titers are shown at
656 the top of each histogram.




658 **Figure S1.** (A) Spearman correlation plot of log MN titers with anti-RBD IgG in COVID-19
 659 patients with different clinical spectrum. Specimens with MN titers less than 10 were assigned a
 660 value of 5. (B) Pie chart comparing fraction of samples with anti-N IgG and neutralizing activity.
 661 (C) Spearman correlation plot between the OD values of anti-N IgG and log MN titers.
 662 Specimens with MN titers less than 10 were assigned a value of 5. (D) Spearman correlation plot
 663 between the OD values of anti-N IgG and anti-N IgG.




664

665 **Figure S2. Comparison of neutralizing antibody responses of COVID-19 patients with**
 666 **different clinical spectrum at different stages of disease progression. (A), (B) and (C) The**
 667 **positive rates of anti-RBD IgG, anti-N IgG and MN titers, respectively. (D), (E) and (E) the**
 668 **exact values of anti-RBD IgG, anti-N IgG and MN titers, respectively.**



669

670 **Figure S3. Kinetics of anti-RBD IgG (A) and MN titers (B) against SARS-CoV-2 of the**
671 **COVID-19 patients with different clinical spectrum during the 480 days follow-up. The**
672 **black solid line represents the fitted curve obtained using the LOESS (locally estimated**
673 **scatterplot smoothing) curve fitting polynomial regression. Gray band areas represent 95%**
674 **confidence intervals.**



675

Table 1. Baseline characteristics and specimens of COVID-19 cases in this study.

Characteristic	COVID-19 cases				P values		
	Total (N=214)	Severe (N=51)	Mild (N=134)	Asymptomatic (N=29)	S vs M	S vs A	M vs A
Median age (range)	48 (2-79)	62 (31-76)	43 (2-79)	25 (7-58)	<0.001	<0.001	<0.001
Age subgroup (N, %)							
<15 yr	12 (5.6)	0 (0)	7 (5.2)	5 (17.2)	NS [#]	0.005	0.040
15-39 yr	74 (34.6)	4 (7.8)	52 (38.8)	18 (62.1)	<0.001	<0.001	0.024
40-59 yr	69 (32.2)	15 (29.4)	48 (36.4)	6 (20.7)	NS [#]	NS [#]	NS [#]
≥60 yr	59 (27.6)	32 (62.7)	27 (20.1)	0 (0)	<0.001	<0.001	0.005
Male (n, %)	100 (46.73)	31 (60.78)	59 (44.03)	10 (34.48)	0.049	0.036	NS [#]
BMI*	23.14 (21.05-25.22)	24.3 (22.18-26.59)	23.05 (21.30-25.11)	20.83 (17.71-23.23)	0.015	<0.001	<0.001
Co-existing chronic medical conditions (n, %)	68 (31.3)	27 (52.9)	35 (26.1)	6 (20.7)	0.001	0.005	NS [#]
Onset to admission, median days (Median, IQR[†])	3 (2-7)	5 (3-7)	3 (1-6)	-	0.006	-	-
Onset to antiviral treatment, median days (Median, IQR)	3 (1-6)	5 (3-8)	3 (1-6)	1 (1-2)	0.012	<0.001	<0.001
Onset to qPCR negative for SARS-CoV-2 (Median, IQR)	18 (12-26)	21 (18-33)	17 (13-25)	9 (5-15)	<0.001	<0.001	<0.001
Duration of hospitalization (Median, IQR)	21 (16-30)	32 (23-40)	20 (16-27.75)	14 (12-19)	<0.001	<0.001	<0.001
Laboratory results, median (Median, IQR)							

NEU ($\times 10^9/L$)	3.12 (2.32-4.08)	3.41 (2.29-4.34)	2.68 (1.85-3.62)	3.44 (2.96-4.3)	0.013	NS [#]	<0.001
LYM ($\times 10^9/L$)	1.36 (0.95-1.78)	0.97 (0.66-1.28)	1.42 (1.13-1.68)	2.13 (1.59-2.61)	<0.001	<0.001	<0.001
ALB (g/dl)	43,4 (40.25-46,15)	39.4 (38.1-42.6)	43.9 (41.9-46.7)	45.3 (43.8-46.9)	<0.001	<0.001	0.004
D-dimer ($\mu\text{g/ml}$)	0.39 (0.24-0.59)	0.56 (0.38-1.14)	0.4 (0.24-0.57)	0.23 (0.22-0.32)	<0.001	<0.001	0.005
CRP (mg/l)	9.93 (1.87-36.15)	44.7 (20.8-76.5)	8.6 (3.22-24.52)	0.62 (0.25-1.94)	<0.001	<0.001	<0.001
IL-6 (pg/ml)	9.25 (2.61-24.47)	29.77 (17.98-50.84)	11.77 (4.02-17.57)	1.96 (1.5-2.94)	<0.001	<0.001	<0.001
PCT (ng/ml)	0.04 (0.03-0.07)	0.06 (0.04-0.09)	0.04 (0.03-0.05)	0.02 (0.02-0.03)	<0.001	<0.001	0.013
LDH (U/l)	222 (178-446.25)	425 (223.5-664.5)	227 (182.5-443.5)	167 (148.5-186.5)	<0.001	<0.001	<0.001
CD4 (count/ul)	550 (388.5-742)	320 (191-423.3)	581 (454-764)	779.5 (673.25-981.3)	<0.001	<0.001	0.003
Samples collected during follow up (N, %)	411	82 (19.95)	251 (61.07)	78 (18.98)	-	-	-
≤ 60 d.a.o [§]	116 (28.2)	37 (45.1)	51 (20.3)	28 (35.9)	-	-	-
61~120 d.a.o	65 (15.8)	4 (4.9)	40 (15.9)	21 (26.9)	-	-	-
121~180 d.a.o	19 (4.6)	3 (3.7)	12 (4.8)	4 (5.1)	-	-	-
181~240 d.a.o	35 (8.5)	2 (2.4)	23 (9.2)	10 (12.8)	-	-	-
241~300 d.a.o	16 (38.9)	0 (0)	12 (4.8)	4 (5.1)	-	-	-
301~360 d.a.o	26 (6.3)	10 (12.2)	15 (6.0)	1 (1.3)	-	-	-
361~420 d.a.o	73 (17.8)	14 (17.1)	51 (20.3)	8 (10.3)	-	-	-
421~480 d.a.o	61 (14.8)	12 (14.6)	47 (18.7)	2 (2.6)	-	-	-
Any exposure to SARS-CoV-2 after discharge (N, %)	0 (0)	0 (0)	0 (0)	0 (0)	-	-	-
Vaccination of SARS-CoV-2 before last follow up (N, %)	0 (0)	0 (0)	0 (0)	0 (0)	-	-	-

*Body Mass Index.

§Days after illness onset.

#Not significant.

†Inter-quartile range.

Table S1. Basic characteristics of plasma samples used in the pseudotyped SARS-CoV-2 neutralization assay.

Patient No.	Sex	Age (range)	Group	Follow-up days (d.a.o [*])	Anti-RBD (OD [§])	MN [#] titer
5	Male	66-70	Severe	458	0.931	80
13	Male	66-70	Severe	378	0.664	20
20	Female	51-55	Severe	471	0.487	40
47	Male	46-50	Severe	434	0.662	160
58	Female	56-60	Mild	412	1.056	320
73	Female	51-55	Mild	470	0.503	40
77	Female	61-65	Mild	477	0.796	80
172	Male	56-60	Mild	423	1.018	160
173	Female	26-30	Mild	449	0.322	10
183	Female	26-30	Mild	477	0.315	20
187	Male	11-15	Asymptomatic	377	0.227	20
190	Female	31-35	Asymptomatic	400	0.243	10
195	Female	56-60	Asymptomatic	453	0.72	160
197	Female	51-55	Asymptomatic	413	0.325	40

*Days after illness onset.

§Optical density.

#Microneutralization.